Red Sun Pharmaceutical: Injection of Nafamostat Mesylate for drug clinical trial approval obtained

Red Sun Pharmaceuticals announced that it has recently received a clinical trial approval notice for injection of nafamostat mesylate from the National Medical Products Administration, allowing them to conduct clinical trials. The drug comes in a 50mg dosage, is classified as a Class 3 chemical drug, and is indicated for preventing blood coagulation during extracorporeal circulation. Injection of nafamostat mesylate can also improve symptoms of pancreatitis and other conditions, as it is a new type of protease inhibitor.